Johnson & Johnson analyst consensus stays supportive, shares trade steadily on the NYSE

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-23, 20:48.

Johnson & Johnson (US4781601046) starts the week on the New York Stock Exchange with a broadly constructive analyst backdrop and stable trading in the Dow Jones Industrial Average. The healthcare heavyweight remains in focus after a series of mid-June clinical trial updates and a steady dividend profile, according to recent market commentary from Wall Street.

What analysts are signaling

On the NYSE, Johnson & Johnson is followed closely by major Wall Street firms, with a consensus tilted toward positive ratings and mid-250 US dollar price targets on several platforms. Finviz data shows that Morgan Stanley, TD Cowen and Leerink Partners all carry Buy or Outperform ratings in 2026, with listed targets between 250 and 265 US dollars, most recently including a Leerink upgrade to Outperform with a 265 dollar objective on May 13, 2026.Finviz analyst overview for JNJ

For UK-based investors, Fidelity’s factsheet for Johnson & Johnson cites a recent trading level around 231.33 US dollars on June 23, 2026 and highlights the shares as part of the drug manufacturers general industry, with a positive total return profile and a history of regular cash dividends.Fidelity data on Johnson & Johnson

How the stock is priced today

Trading snapshots from online broker platforms show Johnson & Johnson shares changing hands on June 23, 2026 in a corridor between roughly 233 and 238 US dollars, with Robinhood quoting an intraday range from 233.37 to 237.85 dollars and a last price around 235.61 dollars in regular NYSE trade.Robinhood quote for JNJ

Another market source, Fidelity, reports a price mark near 231.33 US dollars at 00:59 Eastern time on June 23, 2026, together with a daily move of about 1.27 percent, underlining that the stock continues to trade with typical large-cap liquidity and modest day-to-day volatility for a Dow Jones healthcare constituent.Fidelity JNJ pricing snapshot

The product behind the stock

Johnson & Johnson generates revenue across pharmaceuticals, medical technology and consumer health, with key prescription products including oncology and immunology therapies such as DARZALEX for multiple myeloma and STELARA for immune-mediated inflammatory diseases, alongside a broad range of surgical, vision and orthopaedic devices.

Where the stock trades today

The Johnson & Johnson shares (US4781601046) trade on 2026-06-23, 18:30 Eastern time on the NYSE at 235.61 US dollars, based on Robinhood intraday data for the Dow Jones-listed healthcare group.

This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer to buy or sell securities. Investors should conduct their own research and consider multiple information sources before making investment decisions.